<DOC>
	<DOC>NCT01271777</DOC>
	<brief_summary>The purpose of this study is to demonstrate the efficacy on insulin sensitivity of GFT505 at 80mg/d in male patients with insulin resistance and abdominal obesity. Evaluation will be made using a glucose clamp technique.</brief_summary>
	<brief_title>Pilot Study With GFT505 (80mg) in Patients With Insulin Resistance and Abdominal Obesity</brief_title>
	<detailed_description>The study period per patient is 26 weeks: a selection period will precede a 8-week treatment period, a 6-week wash out period, a second 8-week treatment period in the second arm of treatment and a 2- week follow-up period. Schedule: - Selection visit prior to treatment period (D-14 and D-1) - D0 : randomisation visit - Period T1: first period of treatment with GFT505 80mg or placebo for 8 weeks (D1 to D56) - Wash out period for 6 weeks (D57 to D98) - Period T2: second period of treatment with GFT505 80mg or placebo for 8 weeks (D99 to D154) - Follow up period for 2 weeks (D155 to D169)</detailed_description>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Obesity, Abdominal</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Waist circumference ≥94cm. Body Mass Index ≤ 45kg/m2. Homeostasis Model Assessment of Insulin Resistance (HOMAIR) &gt; 3. Blood Pressure &gt; 160 / 95 mmHg. Diabetes mellitus 1 or 2. Historical of bariatric surgery. Patient treated with a lipiddecreasing medication. A fasting plasma triglycerides concentration &gt; 400mg/dL or a plasma Low Density Lipoprotein Cholesterol (LDLc)concentration &gt; 220mg/dL.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Pre-diabetes</keyword>
	<keyword>Clamp technique</keyword>
	<keyword>PPARs</keyword>
	<keyword>Insulin resistance</keyword>
</DOC>